|
Volumn 17, Issue 8, 2002, Pages 1362-1364
|
Radiocontrast media-induced nephrotoxicity in patients with renal failure: Rationale for a new double-blind, prospective, randomized trial testing calcium channel antagonists
a
HÔTEL DIEU
(France)
|
Author keywords
Atrial natriuretic peptide; Radiocontrast; Renal failure
|
Indexed keywords
AMLODIPINE;
ANTIOXIDANT;
ARGININE;
ATRIAL NATRIURETIC FACTOR;
CALCIUM CHANNEL BLOCKING AGENT;
CONTRAST MEDIUM;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
DIURETIC AGENT;
DOPAMINE;
FUROSEMIDE;
MANNITOL;
NONSTEROID ANTIINFLAMMATORY AGENT;
THEOPHYLLINE;
DIAGNOSTIC AGENT;
RADIOPHARMACEUTICAL AGENT;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CRYSTALLOID;
DOUBLE BLIND PROCEDURE;
DRUG EFFICACY;
HEMODIALYSIS;
HIGH RISK PATIENT;
HUMAN;
KIDNEY FAILURE;
NEPHROTOXICITY;
PATHOGENESIS;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
RISK FACTOR;
DRUG EFFECT;
KIDNEY;
PATHOLOGY;
RADIOGRAPHY;
REVIEW;
CALCIUM CHANNEL BLOCKERS;
CONTRAST MEDIA;
HUMANS;
KIDNEY;
KIDNEY FAILURE;
RADIOPHARMACEUTICALS;
RANDOMIZED CONTROLLED TRIALS;
|
EID: 0035993265
PISSN: 09310509
EISSN: None
Source Type: Journal
DOI: 10.1093/ndt/17.8.1362 Document Type: Article |
Times cited : (21)
|
References (41)
|